Cambridge Healthtech Institute’s 3rd Annual

Antibody-Based Therapies

Driving Breakthrough Therapies

11 November 2025


Cambridge Healthtech Institute’s 16th Annual Antibody-Based Therapies conference showcases cutting-edge developments in antibody platforms including T cell engagers and bi/multispecifics for breakthrough applications in oncology, autoimmune, and other therapeutic areas. Attendees will also gain insights into emerging modalities including radiopharmaceutical conjugates, novel protein degradation technologies, and conditionally active antibody platforms that are dramatically expanding therapeutic possibilities while improving safety profiles. This conference brings together leaders in academia and industry to accelerate transformative therapies from concept to clinic.

Coverage will include, but is not limited to:

T Cell Engagers and Immune-Cell Modulators

  • Next-generation T cell engager designs: trispecifics and multispecifics
  • NK cell engagers and modulators
  • Conditional activation strategies
  • Masked antibody technologies for improved therapeutic index
  • Overcoming limitations of first-generation engagers

Next-Generation Antibodies for Immuno-Oncology

  • PD-1/VEGF tetravalent bispecific antibody
  • PD-1 agonists and cytokine-engaging antibodies
  • Tetravalent TREM2 agonists for Alzheimer's Disease
  • Next-generation immune checkpoint inhibitors
  • Soluble TCR therapy and TCR-like/mimic approaches

Antibodies for Indications beyond Oncology

  • Autoimmunity, Inflammation, and CNS Disorders

Radiopharmaceutical Therapies

  • Antibody-directed radiotherapeutics
  • Novel payload strategies
  • Combination with immunotherapy
  • Theranostic approaches
  • Transforming from peptides to antibody-based approaches
  • Optimising non-antibody scaffolds for radiopharmaceutical delivery

Protein Degraders

  • Targeted protein degradation using antibodies
  • SureTac platform for bispecific cell surface degraders
  • PROTAC-antibody fusions for intracellular targeting
  • Proteolysis-targeting antibodies (PROTABs)
  • Bispecific cell surface degraders

The deadline for priority consideration is 28 March 2025.

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation:


For more details on the conference, please contact:

Mimi Langley
Senior Conference Director
Cambridge Healthtech Institute
Email: mlangley@healthtech.com

For sponsorship information, please contact:

Companies A-K
Jason Gerardi
Sr. Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5452
Email: jgerardi@healthtech.com

Companies L-Z
Ashley Parsons
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1340
Email: ashleyparsons@healthtech.com